Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Vesalius Therapeutics

Request full access

AI-driven drug discovery platform identifying novel gene circuit targets to reverse diseases

Cambridge, United StatesFounded 2019Biotech & Life Sciences

About Vesalius Therapeutics

Vesalius Therapeutics is a biotechnology startup that is revolutionizing the approach to drug development for common diseases. The company operates in the healthcare and pharmaceutical industry, serving patients suffering from diseases that account for 90% of human illness, including heart failure, high blood pressure, type II diabetes, Alzheimer’s disease, NASH, and obesity.

Vesalius Therapeutics' business model is centered on its proprietary ContinuumDiscovery™ platform. This platform uses data science, artificial intelligence, and machine learning to identify previously unrecognized clinical patterns in patient groups. It then links these patterns to the combined effects of multiple genes, identifying optimal drug targets to reverse the disease in these patient groups. The platform also uses proprietary patient-derived, cell-based experimental models to screen and characterize drug candidates.

The company's approach to treating common diseases is unique in that it does not view these diseases as monolithic. Instead, it recognizes that they are a constellation of multiple genetically and biologically distinct diseases that affect patients differently. This fresh approach to diagnosing and treating common diseases is what sets Vesalius Therapeutics apart in the market.

The company generates revenue by developing and commercializing novel drugs based on the findings from its ContinuumDiscovery™ platform. By identifying and targeting the unique genetic and biological characteristics of common diseases, Vesalius Therapeutics aims to develop more effective treatments, thereby creating value for patients and stakeholders.

Source: Dealroom company data

At a glance

Status
Operational
Employees
33
Open positions
1
Dealroom signal
34.4/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Mar 2022 $75M $300M Flagship Pioneering ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Vesalius Therapeutics website traffic

Latest recorded traffic for Vesalius Therapeutics is 2.8K monthly website visits, up 33.3% over the last three months. Vesalius Therapeutics's team declined 10.8% over the past year.

Latest monthly visits2.8K 3-month web change+33.3% 1-year team growth-10.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Vesalius Therapeutics in the Cambridge ecosystem

Live from Dealroom

The Vesalius Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Vesalius Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Vesalius Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.